MyFinsight
Home
Blog
About
Income Statement
|
Cash Flow
|
Balance Sheet
|
Ratios
Income Overview
Net Income
-$37,711K
EPS
-$0.78
Unit: Thousand (K) dollars
Subscribe for Financial Insights
Page 1
Quarterly
123
Page 1
Income Statement
2026-06-30
2026-03-31
2025-12-31
2025-09-30
Research and development
30,985
18,474
23,668*
19,270
General and administrative
9,946
8,791
5,791*
4,656
Total operating expenses
40,931
27,265
29,458
23,926
Loss from operations
-40,931
-27,265
-29,458*
-23,926
Interest and other income, net
3,836
3,748
4,031*
2,308
Net loss
-37,095
-23,517
-25,427*
-21,618
Unrealized loss on marketable securities
-616
-892
94*
143
Reclassification of net gains included in net loss
-
-
14*
-
Total other comprehensive loss
-616
-892
80*
143
Total comprehensive loss
-37,711
-24,409
-25,348
-21,475
Basic EPS
-0.78
-0.5
-0.605
-0.63
Diluted EPS
-0.78
-0.5
-0.605
-0.63
Basic Average Shares
47,696,363
46,576,204
41,873,294
34,198,597
Diluted Average Shares
47,696,363
46,576,204
41,873,294
34,198,597
Page 1
Unit: Thousand (K) dollars (except for numbers of shares and EPS). Numbers labeled with * are estimated quarterly values.
Page 1
Buy us a coffee
Time Plot
Show the time plot by selecting a row from the table.
Income Statement
Total comprehensive
loss
-$37,711K
(-93.86%↓ Y/Y)
Net loss
-$37,095K
(-91.10%↓ Y/Y)
Total other
comprehensive loss
-$616K
(-1366.67%↓ Y/Y)
Interest and other
income, net
$3,836K
(60.23%↑ Y/Y)
Loss from operations
-$40,931K
(-87.71%↓ Y/Y)
Unrealized loss on
marketable securities
-$616K
(-1366.67%↓ Y/Y)
Total operating
expenses
$40,931K
(87.71%↑ Y/Y)
Research and development
$30,985K
(74.82%↑ Y/Y)
General and
administrative
$9,946K
(143.71%↑ Y/Y)
Buy us a coffee
MBX Biosciences, Inc. (MBX)
MBX Biosciences, Inc. (MBX)